SCHEMBL2208975

SCHEMBL2208975

O=C1NS(=O)(=O)c2ccc(F)cc21

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHEK1 O14757 1/20 0.62
DAPK3 O43293 1/20 0.62
MAP4K4 O95819 1/20 0.62
RET P07949 1/20 0.62
PIM1 P11309 1/20 0.62
LTK P29376 1/20 0.62
GRK5 P34947 1/20 0.62
CSNK1A1 P48729 1/20 0.62
CDK8 P49336 1/20 0.62
PRKX P51817 1/20 0.62
LIMK1 P53667 1/20 0.62
CDK5 Q00535 1/20 0.62
ACVR1 Q04771 1/20 0.62
PTK2 Q05397 1/20 0.62
TYRO3 Q06418 1/20 0.62
PRKAA1 Q13131 1/20 0.62
DYRK1A Q13627 1/20 0.62
NTRK3 Q16288 1/20 0.62
LRRK2 Q5S007 1/20 0.62
CLK4 Q9HAZ1 1/20 0.62

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29441946 1.00 CHEK1 (0.62) CHEK1DAPK3MAP4K4RETPIM1
SCHEMBL29350588 0.85 CA12 (0.62) CHEK1DAPK3MAP4K4RETPIM1
SCHEMBL10815413 0.85 CA12 (0.62) CHEK1DAPK3MAP4K4RETPIM1
SCHEMBL29587067 0.78 CA12 (0.53) CHEK1DAPK3MAP4K4RETPIM1
SCHEMBL32689426 0.77 CHEK1 (0.62) CHEK1DAPK3MAP4K4RETPIM1
SCHEMBL3984666 0.77 RET (1.00) CHEK1DAPK3MAP4K4RETPIM1
SCHEMBL3988311 0.77 CA12 (0.73) CHEK1DAPK3MAP4K4RETPIM1
SCHEMBL1684375 0.77 CHEK1 (0.62) CHEK1DAPK3MAP4K4RETPIM1
SCHEMBL30873095 0.77 CA12 (0.73) CHEK1DAPK3MAP4K4RETPIM1
SCHEMBL30016818 0.77 CHEK1 (0.62) CHEK1DAPK3MAP4K4RETPIM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11999758-B2 Inhibitors of the YAP/TAZ-TEAD interaction and their use in the treatment of cancer INVENTIVA (FR) 2024-06-04 US disclosed
CN-113039182-B Inhibitors of YAP/TAZ-TEAD interactions and their use in cancer treatment 伊文蒂瓦公司 2024-02-20 CN disclosed
EP-3860990-B1 INHIBITORS OF THE YAP/TAZ-TEAD INTERACTION AND THEIR USE IN THE TREATMENT OF CANCER INVENTIVA (FR) 2022-09-14 EP disclosed
CN-108368104-B Novel compound inhibitors of the YAP/TAZ-TEAD interaction and their use in the treatment of malignant mesothelioma 伊文蒂瓦公司 2022-01-21 CN disclosed
US-20210323982-A1 INHIBITORS OF THE YAP/TAZ-TEAD INTERACTION AND THEIR USE IN THE TREATMENT OF CANCER INVENTIVA (FR) 2021-10-21 US disclosed
EP-3860990-A1 INHIBITORS OF THE YAP/TAZ-TEAD INTERACTION AND THEIR USE IN THE TREATMENT OF CANCER Inventiva (FR) 2021-08-11 EP disclosed
EP-3362448-B1 NEW COMPOUNDS INHIBITORS OF THE YAP/TAZ-TEAD INTERACTION AND THEIR USE IN THE TREATMENT OF MALIGNANT MESOTHELIOMA INVENTIVA (FR) 2021-08-04 EP disclosed
CN-113039182-A Inhibitors of YAP/TAZ-TEAD interaction and their use in cancer treatment 伊文蒂瓦公司 2021-06-25 CN disclosed
WO-2020070181-A1 INHIBITORS OF THE YAP/TAZ-TEAD INTERACTION AND THEIR USE IN THE TREATMENT OF CANCER INVENTIVA (FR) 2020-04-09 WO disclosed
EP-3632908-A1 INHIBITORS OF THE YAP/TAZ-TEAD INTERACTION AND THEIR USE IN THE TREATMENT OF CANCER Inventiva (FR) 2020-04-08 EP disclosed
US-20090111867-A1 INDOLE ACETIC ACIDS EXHIBITING CRTH2 RECEPTOR ANTAGONISM AND USES THEREOF WYETH (US) 2009-04-30 US disclosed
US-7476667-B2 Indole acetic acids exhibiting CRTH2 receptor antagonism and uses thereof WYETH (US) 2009-01-13 US disclosed
US-20080255100-A1 INDOLE ACETIC ACIDS EXHIBITING CRTH2 RECEPTOR ANTAGONISM AND USES THEREOF WYETH (US) 2008-10-16 US disclosed
US-7405215-B2 Indole acetic acids exhibiting CRTH2 receptor antagonism and uses thereof WYETH (US) 2008-07-29 US disclosed
EP-1805171-A2 INDOLE ACETIC ACIDS EXHIBITING CRTH2 RECEPTOR ANTAGONISM AND USES THEREOF Athersys, Inc. (US) 2007-07-11 EP disclosed
US-20060100425-A1 Indole acetic acids exhibiting CRTH2 receptor antagonism and uses thereof ATHERSYS, INC. 2006-05-11 US disclosed
WO-2006034419-A2 INDOLE ACETIC ACIDS EXHIBITING CRTH2 RECEPTOR ANTAGONISM AND USES THEREOF ATHERSYS, INC. (US) 2006-03-30 WO disclosed
EP-0081955-B1 BENZO-FUSED HETEROCYCLIC COMPOUNDS AMERICAN HOME PRODUCTS CORPORATION (US) 1987-01-21 EP disclosed
US-4490527-A Benzo-fused heterocyclic anti-ulcer agents AMERICAN HOME PRODUCTS CORPORATION (US) 1984-12-25 US disclosed
EP-0081955-A2 Benzo-fused heterocyclic compounds AMERICAN HOME PRODUCTS CORPORATION (US) 1983-06-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060100425-A1 Indole acetic acids exhibiting CRTH2 receptor antagonism and uses thereof PTGDR2, TBXA2R, HCAR2 CHEK1 4591/4885DAPK3 3035/4885MAP4K4 2376/4885
US-20080255100-A1 INDOLE ACETIC ACIDS EXHIBITING CRTH2 RECEPTOR ANTAGONISM AND USES THEREOF PTGDR2, TBXA2R, HCAR2 CHEK1 4591/4885DAPK3 3035/4885MAP4K4 2376/4885
US-20210323982-A1 INHIBITORS OF THE YAP/TAZ-TEAD INTERACTION AND THEIR USE IN THE TREATMENT OF CANCER YAP1, TEAD2, YES1 CHEK1 125/4885DAPK3 247/4885MAP4K4 469/4885
US-20090111867-A1 INDOLE ACETIC ACIDS EXHIBITING CRTH2 RECEPTOR ANTAGONISM AND USES THEREOF PTGDR2, TBXA2R, HCAR2 CHEK1 4591/4885DAPK3 3035/4885MAP4K4 2376/4885
US-11999758-B2 Inhibitors of the YAP/TAZ-TEAD interaction and their use in the treatment of cancer YAP1, TEAD2, YES1 CHEK1 125/4885DAPK3 247/4885MAP4K4 469/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.